As the head of one of the oldest pharmaceutical companies in the world, founded 135 years ago, Menarini Group's CEO Elcin Barker Ergun is proud of the Italian group's heritage while focusing on spearheading its future and creating a firm that will be known not just for commercial excellence but for R&D innovation, specifically in the field of cancer.
Driving Menarini's Future With Decisive Steps
CEO Outlines Strategy And Focus On Oncology
Two years into her tenure as the head of Menarini, Elcin Barker Ergun has already inked two major cancer deals with the acquisition of Stemline and a key licensing pact with Radius Health. The future for the Italian group is bright, she explained to Scrip in an exclusive interview.
